Tectonic Therapeutic Inc.
TECX
Get informed when a big investor buys or sells
+ FollowMarket Cap$528.9M
Close$
$13.78
52.8% downside
Current Fair Value
52.8% downsideOvervalued by 52.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $528.90 Million |
|---|---|
| Enterprise Value | $296.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.05 |
| Beta | 0.1 |
| Outstanding Shares | 18,769,004 |
Return
| Return on Equity | -36.23% |
|---|---|
| Return on Assets | -33.86% |
| Return on Invested Capital | -38.88% |
Valuation & Multiples
| P/E Ratio | -6.28 |
|---|---|
| PEG | -10.71 |
| Price to Sales | - |
| Price to Book Ratio | 2.43 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.27 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 5.03% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.33%▼ 69.05% |
|---|---|
| Total Invested | $40.86M▼ 90.43% |
| Investors Holding | 18▼ 98.00% |
ESG Score
No data
About Tectonic Therapeutic Inc.
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.